{"ticker": {"uuid": "df56ed0d-a8f4-4d23-b0ce-c4990afe8595", "symbol": "NMRA", "name": "Neumora Therapeutics, Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Neumora Therapeutics Target of Unusually Large Options Trading (NASDAQ:NMRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPRWxJbnpNQnlxNm5XOHhmNThFU1hOY1I2SjFhM3JtZ0JSN3dxWXQtQUp0N25Jdk1KRzZaYXh6M2ppWGFBeWctQzVLamtDeFd5bGZfNWg0NVhrQmpLNTNGaFVocHE1RWZteV9raFJVcW5qdU9aODYxbFJGMlQ1UFJEUUV4eVZmU0hUV3MwYlVtbEl4dTczc0hGeE85UlpLVXFzOHNpQjZrUTg4Z2lxVnRMNmFVZVlWQmZEYW1SQU1sMGVGaTdOVmc?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-16T16:49:23+00:00", "published_display": "16 Jul 2026 16:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQSW9mM3I5d1lnaHgzVDlPNFgzSVg3MFNNVmk0N0hLcGh3dko0MF9kWUVzS1phTmdDU1NjUGFZamZZWTBmdnFfanllME9NWmhxd0JiMjJzM3JCQU9SVnY0cEx3T3JnT1pDUlh3Vy0xR1lDem9hZ2ZqdUFXd2UzU1JRbkczUEdHZ1hSRGdTN1JfSHgtLUxQVTBJRjNGbS15Z05pZVd0a25wZl9OX0VjNnp4WHVVOUxxeUVwbTJ1TmdMTzZvcEZVbTkzSDdEUFhvZTdtZC1fb3R2SFZ4ZzQ?oc=5", "source_name": "StockStory", "published_at": "2026-07-15T07:00:00+00:00", "published_display": "15 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Neumora Therapeutics Is Maintained at Outperform by RBC Capital", "summary": "RBC Capital has reiterated its Outperform rating on Neumora Therapeutics. This indicates a continued positive outlook on the company's stock performance.", "url": "https://www.moomoo.com/news/post/72867642/neumora-therapeutics-is-maintained-at-outperform-by-rbc-capital?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-14T08:14:12", "published_display": "14 Jul 2026 08:14", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics (NASDAQ:NMRA) Price Target Cut to $5.00 by Analysts at Royal Bank Of Canada", "summary": "Royal Bank of Canada has reduced its price target for Neumora Therapeutics (NASDAQ:NMRA) from $7.00 to $5.00, while maintaining an \"outperform\" rating. This new target implies a significant upside, despite other analysts like HC Wainwright, Needham, and Mizuho also cutting their ", "url": "https://www.marketbeat.com/instant-alerts/neumora-therapeutics-nasdaqnmra-price-target-cut-to-500-by-analysts-at-royal-bank-of-canada-2026-07-13/", "source_name": "MarketBeat", "published_at": "2026-07-13T14:10:15", "published_display": "13 Jul 2026 14:10", "sentiment": "negative", "sentiment_pct": 36, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "RBC Cuts Price Target on Neumora Therapeutics to $5 From $7, Keeps Outperform, Speculative Risk", "summary": "RBC Capital Markets has reduced its price target for Neumora Therapeutics (NMRA) from $7 to $5, while maintaining an \"Outperform\" rating with a \"Speculative Risk\" assessment. This adjustment comes despite the company's recent inclusion in several Russell indexes, including the Ru", "url": "https://www.marketscreener.com/news/rbc-cuts-price-target-on-neumora-therapeutics-to-5-from-7-keeps-outperform-speculative-risk-ce7f5edfd181f52c", "source_name": "marketscreener.com", "published_at": "2026-07-13T11:10:15", "published_display": "13 Jul 2026 11:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics (NMRA) Stock Sees Fair Value Falls After Navacaprant Discontinuation", "summary": "Neumora Therapeutics (NMRA) has seen its fair value estimate cut by analysts from US$8.91 to US$6.53 per share, a 27% reduction, following the discontinuation of its drug navacaprant. Despite the setback, some analysts remain positive about the company's remaining pipeline, while", "url": "https://finance.yahoo.com/markets/stocks/articles/neumora-therapeutics-nmra-stock-sees-150826430.html", "source_name": "Market source", "published_at": "2026-07-11T09:08:00", "published_display": "11 Jul 2026 09:08", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Quick Look at Today's Ratings for Neumora Therapeutics(NMRA.US), With a Forecast Between $5 to $7", "summary": "This article provides a quick look at analyst ratings for Neumora Therapeutics (NMRA.US), indicating a forecast share price between $5 and $7. The ratings reflect current market sentiment and expert opinions on the company's financial outlook and stock performance. Investors can ", "url": "https://www.moomoo.com/news/post/71603890/a-quick-look-at-today-s-ratings-for-neumora-therapeutics", "source_name": "Moomoo", "published_at": "2026-07-09T20:10:15", "published_display": "09 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 58, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Neumora Therapeutics, Inc. (NMRA) Is One of the Best Get Rich Quick Stocks to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNdk9LZjBpTFZ0Sl8wZEZFRF9rclFROHBfUkEyOWxXMG1JcGVoQTVxd2NUdGxpbzRBME9NTG9yNU0zZnNNanI0Z3FzVmIzbzhPeUVkVjk5UTZrTmxvVTZGZm1LUnpOM200YTRQZzZZT08zMDZ4THRhLXdCZEhUZjJHSWdmUkJPYlFjNklzSENVVG5idnVaaXZCTnhR?oc=5", "source_name": "Market source", "published_at": "2026-07-07T05:53:00+00:00", "published_display": "07 Jul 2026 05:53", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Best Get Rich Quick Stocks to Buy Right Now", "summary": "This article identifies Neumora Therapeutics, Inc. (NASDAQ:NMRA) as a \"get rich quick\" stock with significant upside potential, despite recent price target cuts following negative Phase 3 study outcomes. Analysts express optimism for its \"highly intriguing\" pipeline, which includ", "url": "https://www.insidermonkey.com/blog/5-best-get-rich-quick-stocks-to-buy-right-now-1796261/4/", "source_name": "Insider Monkey", "published_at": "2026-07-06T13:14:00", "published_display": "06 Jul 2026 13:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 3000 Growth Benchmark", "summary": "Neumora Therapeutics, Inc. (NasdaqGS: NMRA) has been added to the Russell 3000 Growth Benchmark, as well as several other Russell indices including the Russell 2000 Index and Russell Microcap Growth Benchmark. This inclusion highlights Neumora's presence in the market as a clinic", "url": "https://www.marketscreener.com/news/neumora-therapeutics-inc-nasdaqgs-nmra-added-to-russell-3000-growth-benchmark-ce7f5fdcd18aff26", "source_name": "marketscreener.com", "published_at": "2026-07-01T08:14:12", "published_display": "01 Jul 2026 08:14", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 3000E Growth Benchmark", "summary": "Neumora Therapeutics, Inc. (NMRA) has been added to the Russell 3000E Growth Benchmark, according to an announcement published on June 29, 2026. This inclusion follows several other additions to various Russell indices on the same day and the prior day, including the Russell 2000", "url": "https://www.marketscreener.com/news/neumora-therapeutics-inc-nasdaqgs-nmra-added-to-russell-3000e-growth-benchmark-ce7f5fdedf8af121", "source_name": "marketscreener.com", "published_at": "2026-06-30T03:39:24", "published_display": "30 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 2000 Index", "summary": "Neumora Therapeutics, Inc. (NasdaqGS: NMRA) has been added to the Russell 2000 Index, as well as several other Russell benchmarks including the Russell 2500 Growth, Russell Microcap Growth, Russell 2000 Growth, Russell 3000E Growth, Russell Microcap, Russell 2000 Dynamic, Russell", "url": "https://www.marketscreener.com/news/neumora-therapeutics-inc-nasdaqgs-nmra-added-to-russell-2000-index-ce7f5fdfdc8ff223", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T22:10:39", "published_display": "29 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 3000 Index", "summary": "Neumora Therapeutics, Inc. (NMRA) has been added to the Russell 3000 Index, along with several other Russell indices including the Russell 2000, Russell 2500 Growth, and Russell Microcap Growth benchmarks. This news follows a recent adjustment by Mizuho, lowering Neumora Therapeu", "url": "https://www.marketscreener.com/news/neumora-therapeutics-inc-nasdaqgs-nmra-added-to-russell-3000-index-ce7f5fdfdf8df727", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T17:42:35", "published_display": "29 Jun 2026 17:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell Microcap Index", "summary": "Neumora Therapeutics, Inc. (NasdaqGS: NMRA) has been added to the Russell Microcap Index. The company is a clinical-stage biopharmaceutical firm focused on neuroscience programs and its most advanced candidate, navacaprant, is in Phase 3 trials for depressive disorder. This inclu", "url": "https://www.marketscreener.com/news/neumora-therapeutics-inc-nasdaqgs-nmra-added-to-russell-microcap-index-ce7f5fdedd88ff2c", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T16:10:48", "published_display": "29 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics, Inc.(NasdaqGS:NMRA) added to Russell 2000 Dynamic Index", "summary": "Neumora Therapeutics, Inc. (NMRA) has been added to the Russell 2000 Dynamic Index, as well as several other Russell indices including the Russell 2000 Index, Russell 2500 Growth Benchmark, and Russell 3000 Index. This inclusion took place around June 28-29, 2026. The company is ", "url": "https://www.marketscreener.com/news/neumora-therapeutics-inc-nasdaqgs-nmra-added-to-russell-2000-dynamic-index-ce7f5fdcdc81f222", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T16:10:48", "published_display": "29 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics, Inc.(NasdaqGS:NMRA) added to Russell Microcap Growth Benchmark Index", "summary": "Neumora Therapeutics, Inc. (NasdaqGS:NMRA) has been added to the Russell Microcap Growth Benchmark Index. This news follows several other index additions for the company, including the Russell 2000 Growth and Russell 3000E Growth benchmarks, despite recent development halts and a", "url": "https://www.marketscreener.com/news/neumora-therapeutics-inc-nasdaqgs-nmra-added-to-russell-microcap-growth-benchmark-index-ce7f5fded08df72d", "source_name": "marketscreener.com", "published_at": "2026-06-29T12:12:35", "published_display": "29 Jun 2026 12:12", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 2000 Growth Benchmark", "summary": "Neumora Therapeutics, Inc. (NasdaqGS:NMRA) has been added to the Russell 2000 Growth Benchmark. This news follows several recent announcements, including its addition to the Russell Microcap Growth Benchmark, Russell 3000E Growth Benchmark, and Russell Microcap Index. The company", "url": "https://www.marketscreener.com/news/neumora-therapeutics-inc-nasdaqgs-nmra-added-to-russell-2000-growth-benchmark-ce7f5fded18df724", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T11:12:35", "published_display": "29 Jun 2026 11:12", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of", "summary": "Levi & Korsinsky has announced an upcoming deadline for a class action lawsuit filed on behalf of investors who suffered losses in Neumora Therapeutics, Inc. (NASDAQ: NMRA) stock. The lawsuit alleges that Neumora Therapeutics made false statements regarding its Phase Three Progra", "url": "https://www.natlawreview.com/press-releases/levi-korsinsky-notifies-neumora-therapeutics-inc-investors-class-action", "source_name": "The National Law Review", "published_at": "2026-06-28T17:40:18", "published_display": "28 Jun 2026 17:40", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NMRA Slides As Neumora Kills Navacaprant After Phase 3 Blowup", "summary": "Neumora Therapeutics Inc. (NMRA) stock slid after the company discontinued its navacaprant program due to failures in Phase 3 trials for major depressive disorder. Analysts have cut price targets significantly, though some maintain Buy or Outperform ratings, citing the company's ", "url": "https://stockstotrade.com/news/neumoratherapeuticsinc-nmra-news-2026_06_28/", "source_name": "StocksToTrade", "published_at": "2026-06-28T15:37:00", "published_display": "28 Jun 2026 15:37", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NMRA Stock Drops As Neumora Axes Failed Depression Drug", "summary": "Neumora Therapeutics Inc. (NMRA) stock has seen an 8.61% increase despite the failure of its Phase 3 navacaprant trials for major depressive disorder, leading to program discontinuation and significant workforce reduction. Analysts have cut price targets but maintained \"Buy\" or \"", "url": "https://www.timothysykes.com/news/neumoratherapeuticsinc-nmra-news-2026_06_28/", "source_name": "Timothy Sykes", "published_at": "2026-06-28T14:40:18", "published_display": "28 Jun 2026 14:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Neumora Therapeutics, Inc. \u2013 NASDAQ:NMRA", "summary": "This article provides the \"Price to book forward\" financial metric for Neumora Therapeutics, Inc. (NASDAQ: NMRA). It details that the data is based on human input and sourced from ICE Data Services and FactSet, with SEC filings from Quartr. The core content is a financial data po", "url": "https://www.tradingview.com/symbols/NASDAQ-NMRA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T18:10:22", "published_display": "27 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NMRA Slides As Neumora Axes Navacaprant After Phase 3 Failure", "summary": "Neumora Therapeutics Inc. (NMRA) stock slid after the company discontinued its navacaprant program due to Phase 3 trial failures in major depressive disorder. Despite significant price target cuts from analysts at H.C. Wainwright, Needham, and Mizuho, the stock maintains generall", "url": "https://www.timothysykes.com/news/neumoratherapeuticsinc-nmra-news-2026_06_27/", "source_name": "Timothy Sykes", "published_at": "2026-06-27T15:10:22", "published_display": "27 Jun 2026 15:10", "sentiment": "negative", "sentiment_pct": 33, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Neumora Therapeutics, Inc. \u2013 NASDAQ:NMRA", "summary": "This article headline from TradingView focuses on the \"Price to sales forward\" metric for Neumora Therapeutics, Inc. (NASDAQ: NMRA). The content indicates that the information is part of a financial data section provided by various financial services. The article itself does not ", "url": "https://www.tradingview.com/symbols/NASDAQ-NMRA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T07:39:55", "published_display": "27 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Neumora Therapeutics, Inc. \u2013 BOATS:NMRA", "summary": "The article references the \"Price to sales forward\" data for Neumora Therapeutics, Inc. (NMRA) available on TradingView under the Blue Ocean Alternative Trade System (BOATS). It appears to be a financial data point without any further analysis or descriptive content, suggesting i", "url": "https://www.tradingview.com/symbols/BOATS-NMRA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T21:39:29", "published_display": "26 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Neumora Therapeutics, Inc. \u2013 BOATS:NMRA", "summary": "This article provides financial information for Neumora Therapeutics, Inc. (NMRA), specifically focusing on its enterprise value to revenue forward ratio. The content appears to be a stub or a section within a larger financial data platform, indicating the data is \"made by humans", "url": "https://www.tradingview.com/symbols/BOATS-NMRA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T06:10:40", "published_display": "26 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics, Inc. Actuals & Estimates (NASDAQ:NMRA)", "summary": "The article provides an overview of Neumora Therapeutics, Inc. (NASDAQ: NMRA) stock performance, financial actuals, and analyst estimates. It includes current stock price, historical highs and lows, volatility, market capitalization, and upcoming earnings report dates. The compan", "url": "https://www.tradingview.com/symbols/NASDAQ-NMRA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T00:50:13", "published_display": "26 Jun 2026 00:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Securities Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $4", "summary": "Mizuho Securities has reiterated its Buy rating on Neumora Therapeutics (NMRA.US) and maintained a target price of $4. This indicates continued analyst confidence in the company's stock performance.", "url": "https://www.moomoo.com/news/post/71830120/mizuho-securities-maintains-neumora-therapeutics-nmraus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-23T12:41:25", "published_display": "23 Jun 2026 12:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora stock price target lowered to $4 by Mizuho on trial failure", "summary": "Mizuho lowered its price target for Neumora Therapeutics (NASDAQ:NMRA) to $4 from $6, while maintaining an Outperform rating, following the failure of its Phase 3 navacaprant trials for depression. The company subsequently announced the discontinuation of the drug and a 35% workf", "url": "https://www.investing.com/news/analyst-ratings/neumora-stock-price-target-lowered-to-4-by-mizuho-on-trial-failure-93CH-4752348", "source_name": "Investing.com", "published_at": "2026-06-22T11:40:59", "published_display": "22 Jun 2026 11:40", "sentiment": "negative", "sentiment_pct": 25, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud", "summary": "Levi & Korsinsky is investigating Neumora Therapeutics (NMRA) for potential securities fraud after the company's stock collapsed due to the failure of two Phase 3 trials for navacaprant and a subsequent 35% workforce reduction. The investigation focuses on whether previous projec", "url": "https://www.businesswire.com/news/home/20260618422337/en/NMRA-Investor-Alert-Levi-Korsinsky-Investigates-Neumora-Therapeutics-NMRA-for-Potential-Securities-Fraud", "source_name": "Business Wire", "published_at": "2026-06-18T14:10:00", "published_display": "18 Jun 2026 14:10", "sentiment": "negative", "sentiment_pct": 9, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Adjusts Price Target on Neumora Therapeutics to $4 From $6, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/mizuho-adjusts-price-target-neumora-121307808.html", "source_name": "MT Newswires", "published_at": "2026-06-18T12:13:07+00:00", "published_display": "18 Jun 2026 12:13", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update", "summary": "Neumora Therapeutics announced that its Phase 3 KOASTAL-2 and -3 studies for navacaprant in Major Depressive Disorder (MDD) did not meet primary or secondary endpoints, leading to the discontinuation of the drug's development. Despite this setback, the company plans to advance ot", "url": "https://finance.yahoo.com/sectors/healthcare/articles/neumora-therapeutics-reports-data-phase-120000811.html", "source_name": "Market source", "published_at": "2026-06-18T12:41:25", "published_display": "18 Jun 2026 12:41", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rx Rundown: Sanofi, Neumora Therapeutics, Uniqure and more", "summary": "This \"Rx Rundown\" article summarizes recent medical marketing news, deal-making, and industry chatter. It covers significant deals and collaborations involving companies like Eli Lilly, Jazz Pharmaceuticals, and Nvidia, alongside FDA approvals and decisions concerning drugs from ", "url": "https://www.mmm-online.com/news/rx-rundown-sanofi-neumora-therapeutics-uniqure/", "source_name": "Medical Marketing and Media", "published_at": "2026-06-18T12:00:00", "published_display": "18 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations", "summary": "SueWallSt has initiated an investigation into Neumora Therapeutics (NASDAQ: NMRA) for potential securities law violations after the company's navacaprant program failed two additional Phase 3 trials and was discontinued, leading to a significant drop in share price. The investiga", "url": "https://www.morningstar.com/news/pr-newswire/20260617ny85254/nmra-shareholder-investigation-suewallst-investigates-neumora-therapeutics-for-possible-securities-law-violations", "source_name": "Morningstar", "published_at": "2026-06-17T13:07:00", "published_display": "17 Jun 2026 13:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Neumora Therapeutics (NMRA) Faces a Major Catalyst From Navacaprant\u2019s Upcoming Depression Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNUGNwdm9ac0ZvakJBREowVEFBNDdydnpRbVU0UnFtUG9SMlhORmtNZEMtRU9EOUFrdUdwZnpoMnFHOWc1eEhRTkJkdnUwNFVxc1FWV0ZpUHFYTXpMU0xuZVhQcFdnZXZVOWE3ellMZkRQMWRrb2phLVZjcmNZcnFndkhZV0FINmJzRldOLUR3bjJVYlkwWnhydjJmNmc?oc=5", "source_name": "Market source", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Three pivotal MDD trial failures for Neumora lead to staffing cuts", "summary": "", "url": "https://finance.yahoo.com/m/504dd820-1f1f-30b5-9740-8cc47980160f/three-pivotal-mdd-trial.html", "source_name": "Clinical Trials Arena", "published_at": "2026-06-16T15:58:51+00:00", "published_display": "16 Jun 2026 15:58", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora depression drug fails; EnGene to cut 50% of staff", "summary": "", "url": "https://finance.yahoo.com/m/c4527e70-17f5-3f54-af91-01ba28ff322c/neumora-depression-drug.html", "source_name": "BioPharma Dive", "published_at": "2026-06-16T09:08:00+00:00", "published_display": "16 Jun 2026 09:08", "sentiment": "positive", "sentiment_pct": 55, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Neumora Therapeutics, Inc. (NMRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE4xR1JsTDk1UG5VM0VHbEFXQklXSTdMUVBFSU96SDdyWWpkYm56UDJSZlBCMkIzVmtOZ3ZvekFpOVYyWFBDcmN6b2d4U2d1NWM5czBoa3BaZmEzZE41aUFOSnVzRkhkekVRMUYyMA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOdVhUTkl6blVTYm5qczl2dXEyRHJHMjFmQlpFVTFKeDJLQndGNHI2MzNRYlRBTDFVYm1yZGlnbC1ZU3NybUljbjh0RGhtV2ZhNkFZczRzOVZmT2Q3R1JYX3g2OG1JbV85bk1FNG1qdUlLLWFJRkRJdXB6YXlJWThVa0daeVNDbTZxM3hVQUZ4Uk9JYUtfRVE?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAJBVV95cUxQVWhmVGNqd1NMMk5JSWp6d01IMEVIdWtkSUdLeV9PbjQxUDBjY19zWTUycE1zdVc5LXVGWmpmeVhQNlRlSlRzcFVCQkVTb1RYcVdscHl3S0J1OUtyRV9BSlZiRWZnMUxJdHpXU0tMRERtajJvZzZMMzZyRWVtRjNaeTJPVE51blRvT2pWUjI3SU1ManFQeVdMNndqb3kxS3RBZXpEVEVOR205anNiZDdfN2JJYlV1OTY2NVJHVWRGX3VBbV9sU2VuUGN3aWxvWDU5RDBoWTAyTExYMG1ZYW9kWDV6b29SQ0lUc1VsMjBMbkplVi0tUVZlNFVTUWhvRk1oaUF0bGtVQ1E1U3BEZkh3MDZwOFk2TTN1?oc=5", "source_name": "Morningstar", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NMRA Stock On Track For Worst Day In 1.5 Years \u2014 Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwJBVV95cUxOSGN5QnJTM05kZDlDbW51SlByZXBjZnd1N1BNaDR5Szdac2Zxc2FLdmdaOTlFSmc3SU9EN0tqNDRZUDlYYWFHaHFnTmRNZnNrdng2Y3lyRjN6RnIzdmladnFkTkVVUnByRmlPdmlUaHo0VjdITFJuMzBOQ1drY2hZQTgxQUNoaFBvWFdJcEhBczBCWWpxOHlCTnF5NlZPY1IxZG1vSjVDTmxmWUNCM1Y2bHJNWldPckx6RlVscnhBd1NzOWVFa0VmRWx5WkpMQWl2OHZCTkZZUGVWYkRvUkNRYVV3TVVrTElpSlNxcEo1RG9rZXBlUlZLQWxDeU9GRE5YT2MtWWlzTQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora scraps depression drug, cuts 35% of staff, refocuses pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxON3JPYUdGbk03cHJjUkxGWTUxSWlsTDRCQ3hKLVBRY2FsSnVyQThGN1FWS2xPelVvYW1xbWNjWHpOMkd3QjNSUmt1MDM0UnlkVU50ZC1JUlVkMjh1VzVKTW54U0Q3d2x5QS1taklxTWZRUVdNX1B5dUMtNUtTSXlDdHppcUV4cnZTaHpkZWtxVGN0ZmlTNUZCRE1uellGZm10QjFQalhQQ3l5WHZEODFLQkZFOUcySkxfZEFrV19n?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "NMRA Stock Price and Chart \u2014 NASDAQ:NMRA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE4zdnptN2gxMlBkY1p2MzU1aDFJQl9wUkt4WTQzSEx3VWlDNDIwZzUzYzFicTE3Umw0YWFUWHhGTi10czRKdm8tdzJTd3VMQ3lGanRuVjFuYVVrMVBu?oc=5", "source_name": "TradingView", "published_at": "2026-04-18T07:00:00+00:00", "published_display": "18 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics (NMRA) Is Among the Best Penny Stocks Set to Explode", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPWTR5NF9IWUJMazF1bUh3ZjNvYzNVSlVzNEpXcjBmQWZrNjR1alBnUHVkdS1ONEhSdS1lTGhNSkxGcmlvby1ESDV3OGRxSkpDcXBVNmdQWGRtZDdIb09DM0dfUjFnWlUwaUpSZ3RDd1IwNHJmazMwM3BycFZMcy1Nd1RqZlFBYl9xVERaS2FnSDFSUFc4NWQxOUROb1FsVldDd1Z1b2VJQnM?oc=5", "source_name": "Market source", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora lines up April 13 Needham healthcare conference webcast", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPT1hzS0lBSktyYXVUMUlNMHRoSnVJLVdQUGJtN0p3RU16RjJ4QWlmT2lMQlFKZWRKUGlfdDhBSTJERmtHZkEwN3V4MlVtYW1lVnRsRzVkZjZMVFA3R0dSU1E1ZmtfYW1zMTBjdGtCbWcxQ3c5c3NFcGJfX1FKcTBQSEg0NnpYamJuWHlBanBidXVPRktwSUo1V0xkZXJuRVBmZ2MxZEpvRTgyZ0Rvay0xUHVVZGlIRnJSbmJHaDVR?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Neumora Therapeutics (NMRA) Positioned to Capitalize on Blockbuster Opportunity", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQMEhoZWJJeU1xMklfcWNOaVkxeVhtcDlKeXBKMGtyT1J0ZHQ0cnhySHJEQmZNaEJ6OG1obnE2TTFSbFRVS0NtcDJhUTcyc3N0Y1NFNlJlVGh2enlWNG1lMG01elRtY0k5Zy11cXNhNXIzaTlTZ2txUk9nWHJmNTEta0lEUC1EMGtHUFM3Sld2NEN6RnFGek1waw?oc=5", "source_name": "Market source", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics Inc (NMRA) Sheds More Light on Phase 1b Study of NMRA-511", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQT2tmOUJ3akZkZ1RabVVxZTdDQTVCb1hGTHBxYXAyXzJuS2lkS3NqREFFRElscTJGU0szRzhLVHQwYk9fb2JrTDFkNFhfOHhJNzN5ZWFfM1VVOWdlT1Rnd0xuWE9Tc0RsejhXckEtMHN6cVB5QWthY21zbUpBMlhNYlBzUXd3Mjdk?oc=5", "source_name": "Market source", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Neumora Therapeutics\u2019 (NMRA) Guggenheim Spotlight Recast Its Core Neuroscience Investment Narrative?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Sees Upside Potential in Neumora Therapeutics (NMRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNTUxuVFFxQXMzalR2TXZTdldxTHh4R2JDc2pHTTNYUWZwZmd3MW9GR0dONlRpQnhZODVzakxubVNIR3VrTlluRXVwNjBLSTBRZUc0emJiNEJhWlV4OXhrdEN0UndTRG5BS1hLUFBlejZob3pTTFFjei1YUHd5RW5XZFhrWVZ5Zw?oc=5", "source_name": "Market source", "published_at": "2026-01-03T08:00:00+00:00", "published_display": "03 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics\u2019 Experimental Drug Demonstrates Weight Loss in Preclinical Studies", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxOSWhuQmR0WVFZU3plaC1BUXVkc0szYllCWTRJSFVadVFfVjVhRHN0MjJUM0R3QmJqUjdibDJ4ZWhNRFpMWVY2MUNtdm1zakZMNkk0bDJWRUI3amp6MDQySWpkT24yaV9ZT2lZaVFodlBrMVRQVG1LcWtpYmVSQVhYV3YxakhVU1F1WmwzMkNmb2x5RlNMdVZPTVp3VVRBM0lhVEVJbUI0ZWNxUDBoTDh2YXVpV0IyWW40cS0teUFwWEdFQk9QZmR2a05McXpGd2xXYmpIbmxWdlFoWTRUWl85Y2NPam4?oc=5", "source_name": "Stocktwits", "published_at": "2025-10-26T07:00:00+00:00", "published_display": "26 Oct 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics to Host Virtual R&D Day Highlighting Innovative Therapeutics Pipeline on October 27, 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNbjNYaTZ3MWdFSnJPand6VmVKX1lUUUYtQlVjVFpPX0FtODVKSEw0TmNUV1dqZzhqd003eFE2VFVpV3JuWkFGWU00WS1RSHNOV0tNbFlNdTZFcTZTSVBBS3c3ZFhXRTI5WnpqcDdYenBpNXpWamxzQmNfelNuVGNsQ21qTFk5dkc1N1BYWHBfNFdWUWRaeE5yWTZnd0hLZG4xb05yQkYwRXdfcGNXSTNsTGtnSllrOFdUeGZZQ2xSWjQ5bHZvWEpKMWZNdXpLWnN6d0l4VmJEOTlqRWNXX1ZvZQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-10-01T07:00:00+00:00", "published_display": "01 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NEUMORA THERAPEUTICS, INC. (NASDAQ: NMRA) DEADLINE ALERT:", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAJBVV95cUxOSHpiejJZZmdvX2dUTnRuWkt6SVYtZm1PSkhFbXVneTlSQmcxMDBEd2VnUndqd2g3NUFQR0NtRXFuVEZoOC1qRHFhNXpyUXh5YUltOHFoTzd4b0lOTkdSRkZIWS1JQWFZUXZfVE9MRUQtdm4wd05pckZZNFNocldjQkgtZXRJY3VUTEdIVDcyTTItQk94c3BNeXNzMzVWUUpscl9idXdCZ2k5SlBqVVRoUEZhUk5Ga2pYVEVrVXNTdGFjSnJwLVZsR2lfTWlsMDVYNk91LTV5eFZheEwyQlBnYnVtRVFuWFc5ZVQ4S043bFctR2hBbjk3OTYwNWd6VzYzemVyeXBxYmpCQndBZENYc1FOcXZHWV9CSUFZQlMzNllGSk1FY0l1RnJlY3I2M01JRjZXOQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-02-18T08:00:00+00:00", "published_display": "18 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Neumora Therapeutics Target of Unusually Large Options Trading (NASDAQ:NMRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPRWxJbnpNQnlxNm5XOHhmNThFU1hOY1I2SjFhM3JtZ0JSN3dxWXQtQUp0N25Jdk1KRzZaYXh6M2ppWGFBeWctQzVLamtDeFd5bGZfNWg0NVhrQmpLNTNGaFVocHE1RWZteV9raFJVcW5qdU9aODYxbFJGMlQ1UFJEUUV4eVZmU0hUV3MwYlVtbEl4dTczc0hGeE85UlpLVXFzOHNpQjZrUTg4Z2lxVnRMNmFVZVlWQmZEYW1SQU1sMGVGaTdOVmc?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-16T16:49:23+00:00", "published_display": "16 Jul 2026 16:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics Is Maintained at Outperform by RBC Capital", "summary": "RBC Capital has reiterated its Outperform rating on Neumora Therapeutics. This indicates a continued positive outlook on the company's stock performance.", "url": "https://www.moomoo.com/news/post/72867642/neumora-therapeutics-is-maintained-at-outperform-by-rbc-capital?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-14T08:14:12", "published_display": "14 Jul 2026 08:14", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics (NASDAQ:NMRA) Price Target Cut to $5.00 by Analysts at Royal Bank Of Canada", "summary": "Royal Bank of Canada has reduced its price target for Neumora Therapeutics (NASDAQ:NMRA) from $7.00 to $5.00, while maintaining an \"outperform\" rating. This new target implies a significant upside, despite other analysts like HC Wainwright, Needham, and Mizuho also cutting their ", "url": "https://www.marketbeat.com/instant-alerts/neumora-therapeutics-nasdaqnmra-price-target-cut-to-500-by-analysts-at-royal-bank-of-canada-2026-07-13/", "source_name": "MarketBeat", "published_at": "2026-07-13T14:10:15", "published_display": "13 Jul 2026 14:10", "sentiment": "negative", "sentiment_pct": 36, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Cuts Price Target on Neumora Therapeutics to $5 From $7, Keeps Outperform, Speculative Risk", "summary": "RBC Capital Markets has reduced its price target for Neumora Therapeutics (NMRA) from $7 to $5, while maintaining an \"Outperform\" rating with a \"Speculative Risk\" assessment. This adjustment comes despite the company's recent inclusion in several Russell indexes, including the Ru", "url": "https://www.marketscreener.com/news/rbc-cuts-price-target-on-neumora-therapeutics-to-5-from-7-keeps-outperform-speculative-risk-ce7f5edfd181f52c", "source_name": "marketscreener.com", "published_at": "2026-07-13T11:10:15", "published_display": "13 Jul 2026 11:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics (NMRA) Stock Sees Fair Value Falls After Navacaprant Discontinuation", "summary": "Neumora Therapeutics (NMRA) has seen its fair value estimate cut by analysts from US$8.91 to US$6.53 per share, a 27% reduction, following the discontinuation of its drug navacaprant. Despite the setback, some analysts remain positive about the company's remaining pipeline, while", "url": "https://finance.yahoo.com/markets/stocks/articles/neumora-therapeutics-nmra-stock-sees-150826430.html", "source_name": "Market source", "published_at": "2026-07-11T09:08:00", "published_display": "11 Jul 2026 09:08", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Quick Look at Today's Ratings for Neumora Therapeutics(NMRA.US), With a Forecast Between $5 to $7", "summary": "This article provides a quick look at analyst ratings for Neumora Therapeutics (NMRA.US), indicating a forecast share price between $5 and $7. The ratings reflect current market sentiment and expert opinions on the company's financial outlook and stock performance. Investors can ", "url": "https://www.moomoo.com/news/post/71603890/a-quick-look-at-today-s-ratings-for-neumora-therapeutics", "source_name": "Moomoo", "published_at": "2026-07-09T20:10:15", "published_display": "09 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 58, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Neumora Therapeutics, Inc. (NMRA) Is One of the Best Get Rich Quick Stocks to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNdk9LZjBpTFZ0Sl8wZEZFRF9rclFROHBfUkEyOWxXMG1JcGVoQTVxd2NUdGxpbzRBME9NTG9yNU0zZnNNanI0Z3FzVmIzbzhPeUVkVjk5UTZrTmxvVTZGZm1LUnpOM200YTRQZzZZT08zMDZ4THRhLXdCZEhUZjJHSWdmUkJPYlFjNklzSENVVG5idnVaaXZCTnhR?oc=5", "source_name": "Market source", "published_at": "2026-07-07T05:53:00+00:00", "published_display": "07 Jul 2026 05:53", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Best Get Rich Quick Stocks to Buy Right Now", "summary": "This article identifies Neumora Therapeutics, Inc. (NASDAQ:NMRA) as a \"get rich quick\" stock with significant upside potential, despite recent price target cuts following negative Phase 3 study outcomes. Analysts express optimism for its \"highly intriguing\" pipeline, which includ", "url": "https://www.insidermonkey.com/blog/5-best-get-rich-quick-stocks-to-buy-right-now-1796261/4/", "source_name": "Insider Monkey", "published_at": "2026-07-06T13:14:00", "published_display": "06 Jul 2026 13:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 3000 Growth Benchmark", "summary": "Neumora Therapeutics, Inc. (NasdaqGS: NMRA) has been added to the Russell 3000 Growth Benchmark, as well as several other Russell indices including the Russell 2000 Index and Russell Microcap Growth Benchmark. This inclusion highlights Neumora's presence in the market as a clinic", "url": "https://www.marketscreener.com/news/neumora-therapeutics-inc-nasdaqgs-nmra-added-to-russell-3000-growth-benchmark-ce7f5fdcd18aff26", "source_name": "marketscreener.com", "published_at": "2026-07-01T08:14:12", "published_display": "01 Jul 2026 08:14", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 3000E Growth Benchmark", "summary": "Neumora Therapeutics, Inc. (NMRA) has been added to the Russell 3000E Growth Benchmark, according to an announcement published on June 29, 2026. This inclusion follows several other additions to various Russell indices on the same day and the prior day, including the Russell 2000", "url": "https://www.marketscreener.com/news/neumora-therapeutics-inc-nasdaqgs-nmra-added-to-russell-3000e-growth-benchmark-ce7f5fdedf8af121", "source_name": "marketscreener.com", "published_at": "2026-06-30T03:39:24", "published_display": "30 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 2000 Index", "summary": "Neumora Therapeutics, Inc. (NasdaqGS: NMRA) has been added to the Russell 2000 Index, as well as several other Russell benchmarks including the Russell 2500 Growth, Russell Microcap Growth, Russell 2000 Growth, Russell 3000E Growth, Russell Microcap, Russell 2000 Dynamic, Russell", "url": "https://www.marketscreener.com/news/neumora-therapeutics-inc-nasdaqgs-nmra-added-to-russell-2000-index-ce7f5fdfdc8ff223", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T22:10:39", "published_display": "29 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 3000 Index", "summary": "Neumora Therapeutics, Inc. (NMRA) has been added to the Russell 3000 Index, along with several other Russell indices including the Russell 2000, Russell 2500 Growth, and Russell Microcap Growth benchmarks. This news follows a recent adjustment by Mizuho, lowering Neumora Therapeu", "url": "https://www.marketscreener.com/news/neumora-therapeutics-inc-nasdaqgs-nmra-added-to-russell-3000-index-ce7f5fdfdf8df727", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T17:42:35", "published_display": "29 Jun 2026 17:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell Microcap Index", "summary": "Neumora Therapeutics, Inc. (NasdaqGS: NMRA) has been added to the Russell Microcap Index. The company is a clinical-stage biopharmaceutical firm focused on neuroscience programs and its most advanced candidate, navacaprant, is in Phase 3 trials for depressive disorder. This inclu", "url": "https://www.marketscreener.com/news/neumora-therapeutics-inc-nasdaqgs-nmra-added-to-russell-microcap-index-ce7f5fdedd88ff2c", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T16:10:48", "published_display": "29 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics, Inc.(NasdaqGS:NMRA) added to Russell 2000 Dynamic Index", "summary": "Neumora Therapeutics, Inc. (NMRA) has been added to the Russell 2000 Dynamic Index, as well as several other Russell indices including the Russell 2000 Index, Russell 2500 Growth Benchmark, and Russell 3000 Index. This inclusion took place around June 28-29, 2026. The company is ", "url": "https://www.marketscreener.com/news/neumora-therapeutics-inc-nasdaqgs-nmra-added-to-russell-2000-dynamic-index-ce7f5fdcdc81f222", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T16:10:48", "published_display": "29 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics, Inc.(NasdaqGS:NMRA) added to Russell Microcap Growth Benchmark Index", "summary": "Neumora Therapeutics, Inc. (NasdaqGS:NMRA) has been added to the Russell Microcap Growth Benchmark Index. This news follows several other index additions for the company, including the Russell 2000 Growth and Russell 3000E Growth benchmarks, despite recent development halts and a", "url": "https://www.marketscreener.com/news/neumora-therapeutics-inc-nasdaqgs-nmra-added-to-russell-microcap-growth-benchmark-index-ce7f5fded08df72d", "source_name": "marketscreener.com", "published_at": "2026-06-29T12:12:35", "published_display": "29 Jun 2026 12:12", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 2000 Growth Benchmark", "summary": "Neumora Therapeutics, Inc. (NasdaqGS:NMRA) has been added to the Russell 2000 Growth Benchmark. This news follows several recent announcements, including its addition to the Russell Microcap Growth Benchmark, Russell 3000E Growth Benchmark, and Russell Microcap Index. The company", "url": "https://www.marketscreener.com/news/neumora-therapeutics-inc-nasdaqgs-nmra-added-to-russell-2000-growth-benchmark-ce7f5fded18df724", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T11:12:35", "published_display": "29 Jun 2026 11:12", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of", "summary": "Levi & Korsinsky has announced an upcoming deadline for a class action lawsuit filed on behalf of investors who suffered losses in Neumora Therapeutics, Inc. (NASDAQ: NMRA) stock. The lawsuit alleges that Neumora Therapeutics made false statements regarding its Phase Three Progra", "url": "https://www.natlawreview.com/press-releases/levi-korsinsky-notifies-neumora-therapeutics-inc-investors-class-action", "source_name": "The National Law Review", "published_at": "2026-06-28T17:40:18", "published_display": "28 Jun 2026 17:40", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NMRA Slides As Neumora Kills Navacaprant After Phase 3 Blowup", "summary": "Neumora Therapeutics Inc. (NMRA) stock slid after the company discontinued its navacaprant program due to failures in Phase 3 trials for major depressive disorder. Analysts have cut price targets significantly, though some maintain Buy or Outperform ratings, citing the company's ", "url": "https://stockstotrade.com/news/neumoratherapeuticsinc-nmra-news-2026_06_28/", "source_name": "StocksToTrade", "published_at": "2026-06-28T15:37:00", "published_display": "28 Jun 2026 15:37", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NMRA Stock Drops As Neumora Axes Failed Depression Drug", "summary": "Neumora Therapeutics Inc. (NMRA) stock has seen an 8.61% increase despite the failure of its Phase 3 navacaprant trials for major depressive disorder, leading to program discontinuation and significant workforce reduction. Analysts have cut price targets but maintained \"Buy\" or \"", "url": "https://www.timothysykes.com/news/neumoratherapeuticsinc-nmra-news-2026_06_28/", "source_name": "Timothy Sykes", "published_at": "2026-06-28T14:40:18", "published_display": "28 Jun 2026 14:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Neumora Therapeutics, Inc. \u2013 NASDAQ:NMRA", "summary": "This article provides the \"Price to book forward\" financial metric for Neumora Therapeutics, Inc. (NASDAQ: NMRA). It details that the data is based on human input and sourced from ICE Data Services and FactSet, with SEC filings from Quartr. The core content is a financial data po", "url": "https://www.tradingview.com/symbols/NASDAQ-NMRA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T18:10:22", "published_display": "27 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NMRA Slides As Neumora Axes Navacaprant After Phase 3 Failure", "summary": "Neumora Therapeutics Inc. (NMRA) stock slid after the company discontinued its navacaprant program due to Phase 3 trial failures in major depressive disorder. Despite significant price target cuts from analysts at H.C. Wainwright, Needham, and Mizuho, the stock maintains generall", "url": "https://www.timothysykes.com/news/neumoratherapeuticsinc-nmra-news-2026_06_27/", "source_name": "Timothy Sykes", "published_at": "2026-06-27T15:10:22", "published_display": "27 Jun 2026 15:10", "sentiment": "negative", "sentiment_pct": 33, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Neumora Therapeutics, Inc. \u2013 NASDAQ:NMRA", "summary": "This article headline from TradingView focuses on the \"Price to sales forward\" metric for Neumora Therapeutics, Inc. (NASDAQ: NMRA). The content indicates that the information is part of a financial data section provided by various financial services. The article itself does not ", "url": "https://www.tradingview.com/symbols/NASDAQ-NMRA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T07:39:55", "published_display": "27 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Neumora Therapeutics, Inc. \u2013 BOATS:NMRA", "summary": "The article references the \"Price to sales forward\" data for Neumora Therapeutics, Inc. (NMRA) available on TradingView under the Blue Ocean Alternative Trade System (BOATS). It appears to be a financial data point without any further analysis or descriptive content, suggesting i", "url": "https://www.tradingview.com/symbols/BOATS-NMRA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T21:39:29", "published_display": "26 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Neumora Therapeutics, Inc. \u2013 BOATS:NMRA", "summary": "This article provides financial information for Neumora Therapeutics, Inc. (NMRA), specifically focusing on its enterprise value to revenue forward ratio. The content appears to be a stub or a section within a larger financial data platform, indicating the data is \"made by humans", "url": "https://www.tradingview.com/symbols/BOATS-NMRA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T06:10:40", "published_display": "26 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics, Inc. Actuals & Estimates (NASDAQ:NMRA)", "summary": "The article provides an overview of Neumora Therapeutics, Inc. (NASDAQ: NMRA) stock performance, financial actuals, and analyst estimates. It includes current stock price, historical highs and lows, volatility, market capitalization, and upcoming earnings report dates. The compan", "url": "https://www.tradingview.com/symbols/NASDAQ-NMRA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T00:50:13", "published_display": "26 Jun 2026 00:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Securities Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $4", "summary": "Mizuho Securities has reiterated its Buy rating on Neumora Therapeutics (NMRA.US) and maintained a target price of $4. This indicates continued analyst confidence in the company's stock performance.", "url": "https://www.moomoo.com/news/post/71830120/mizuho-securities-maintains-neumora-therapeutics-nmraus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-23T12:41:25", "published_display": "23 Jun 2026 12:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora stock price target lowered to $4 by Mizuho on trial failure", "summary": "Mizuho lowered its price target for Neumora Therapeutics (NASDAQ:NMRA) to $4 from $6, while maintaining an Outperform rating, following the failure of its Phase 3 navacaprant trials for depression. The company subsequently announced the discontinuation of the drug and a 35% workf", "url": "https://www.investing.com/news/analyst-ratings/neumora-stock-price-target-lowered-to-4-by-mizuho-on-trial-failure-93CH-4752348", "source_name": "Investing.com", "published_at": "2026-06-22T11:40:59", "published_display": "22 Jun 2026 11:40", "sentiment": "negative", "sentiment_pct": 25, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud", "summary": "Levi & Korsinsky is investigating Neumora Therapeutics (NMRA) for potential securities fraud after the company's stock collapsed due to the failure of two Phase 3 trials for navacaprant and a subsequent 35% workforce reduction. The investigation focuses on whether previous projec", "url": "https://www.businesswire.com/news/home/20260618422337/en/NMRA-Investor-Alert-Levi-Korsinsky-Investigates-Neumora-Therapeutics-NMRA-for-Potential-Securities-Fraud", "source_name": "Business Wire", "published_at": "2026-06-18T14:10:00", "published_display": "18 Jun 2026 14:10", "sentiment": "negative", "sentiment_pct": 9, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Adjusts Price Target on Neumora Therapeutics to $4 From $6, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/mizuho-adjusts-price-target-neumora-121307808.html", "source_name": "MT Newswires", "published_at": "2026-06-18T12:13:07+00:00", "published_display": "18 Jun 2026 12:13", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update", "summary": "Neumora Therapeutics announced that its Phase 3 KOASTAL-2 and -3 studies for navacaprant in Major Depressive Disorder (MDD) did not meet primary or secondary endpoints, leading to the discontinuation of the drug's development. Despite this setback, the company plans to advance ot", "url": "https://finance.yahoo.com/sectors/healthcare/articles/neumora-therapeutics-reports-data-phase-120000811.html", "source_name": "Market source", "published_at": "2026-06-18T12:41:25", "published_display": "18 Jun 2026 12:41", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rx Rundown: Sanofi, Neumora Therapeutics, Uniqure and more", "summary": "This \"Rx Rundown\" article summarizes recent medical marketing news, deal-making, and industry chatter. It covers significant deals and collaborations involving companies like Eli Lilly, Jazz Pharmaceuticals, and Nvidia, alongside FDA approvals and decisions concerning drugs from ", "url": "https://www.mmm-online.com/news/rx-rundown-sanofi-neumora-therapeutics-uniqure/", "source_name": "Medical Marketing and Media", "published_at": "2026-06-18T12:00:00", "published_display": "18 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations", "summary": "SueWallSt has initiated an investigation into Neumora Therapeutics (NASDAQ: NMRA) for potential securities law violations after the company's navacaprant program failed two additional Phase 3 trials and was discontinued, leading to a significant drop in share price. The investiga", "url": "https://www.morningstar.com/news/pr-newswire/20260617ny85254/nmra-shareholder-investigation-suewallst-investigates-neumora-therapeutics-for-possible-securities-law-violations", "source_name": "Morningstar", "published_at": "2026-06-17T13:07:00", "published_display": "17 Jun 2026 13:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Neumora Therapeutics (NMRA) Faces a Major Catalyst From Navacaprant\u2019s Upcoming Depression Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNUGNwdm9ac0ZvakJBREowVEFBNDdydnpRbVU0UnFtUG9SMlhORmtNZEMtRU9EOUFrdUdwZnpoMnFHOWc1eEhRTkJkdnUwNFVxc1FWV0ZpUHFYTXpMU0xuZVhQcFdnZXZVOWE3ellMZkRQMWRrb2phLVZjcmNZcnFndkhZV0FINmJzRldOLUR3bjJVYlkwWnhydjJmNmc?oc=5", "source_name": "Market source", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Three pivotal MDD trial failures for Neumora lead to staffing cuts", "summary": "", "url": "https://finance.yahoo.com/m/504dd820-1f1f-30b5-9740-8cc47980160f/three-pivotal-mdd-trial.html", "source_name": "Clinical Trials Arena", "published_at": "2026-06-16T15:58:51+00:00", "published_display": "16 Jun 2026 15:58", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora depression drug fails; EnGene to cut 50% of staff", "summary": "", "url": "https://finance.yahoo.com/m/c4527e70-17f5-3f54-af91-01ba28ff322c/neumora-depression-drug.html", "source_name": "BioPharma Dive", "published_at": "2026-06-16T09:08:00+00:00", "published_display": "16 Jun 2026 09:08", "sentiment": "positive", "sentiment_pct": 55, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Neumora Therapeutics, Inc. (NMRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE4xR1JsTDk1UG5VM0VHbEFXQklXSTdMUVBFSU96SDdyWWpkYm56UDJSZlBCMkIzVmtOZ3ZvekFpOVYyWFBDcmN6b2d4U2d1NWM5czBoa3BaZmEzZE41aUFOSnVzRkhkekVRMUYyMA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOdVhUTkl6blVTYm5qczl2dXEyRHJHMjFmQlpFVTFKeDJLQndGNHI2MzNRYlRBTDFVYm1yZGlnbC1ZU3NybUljbjh0RGhtV2ZhNkFZczRzOVZmT2Q3R1JYX3g2OG1JbV85bk1FNG1qdUlLLWFJRkRJdXB6YXlJWThVa0daeVNDbTZxM3hVQUZ4Uk9JYUtfRVE?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAJBVV95cUxQVWhmVGNqd1NMMk5JSWp6d01IMEVIdWtkSUdLeV9PbjQxUDBjY19zWTUycE1zdVc5LXVGWmpmeVhQNlRlSlRzcFVCQkVTb1RYcVdscHl3S0J1OUtyRV9BSlZiRWZnMUxJdHpXU0tMRERtajJvZzZMMzZyRWVtRjNaeTJPVE51blRvT2pWUjI3SU1ManFQeVdMNndqb3kxS3RBZXpEVEVOR205anNiZDdfN2JJYlV1OTY2NVJHVWRGX3VBbV9sU2VuUGN3aWxvWDU5RDBoWTAyTExYMG1ZYW9kWDV6b29SQ0lUc1VsMjBMbkplVi0tUVZlNFVTUWhvRk1oaUF0bGtVQ1E1U3BEZkh3MDZwOFk2TTN1?oc=5", "source_name": "Morningstar", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NMRA Stock On Track For Worst Day In 1.5 Years \u2014 Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwJBVV95cUxOSGN5QnJTM05kZDlDbW51SlByZXBjZnd1N1BNaDR5Szdac2Zxc2FLdmdaOTlFSmc3SU9EN0tqNDRZUDlYYWFHaHFnTmRNZnNrdng2Y3lyRjN6RnIzdmladnFkTkVVUnByRmlPdmlUaHo0VjdITFJuMzBOQ1drY2hZQTgxQUNoaFBvWFdJcEhBczBCWWpxOHlCTnF5NlZPY1IxZG1vSjVDTmxmWUNCM1Y2bHJNWldPckx6RlVscnhBd1NzOWVFa0VmRWx5WkpMQWl2OHZCTkZZUGVWYkRvUkNRYVV3TVVrTElpSlNxcEo1RG9rZXBlUlZLQWxDeU9GRE5YT2MtWWlzTQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora scraps depression drug, cuts 35% of staff, refocuses pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxON3JPYUdGbk03cHJjUkxGWTUxSWlsTDRCQ3hKLVBRY2FsSnVyQThGN1FWS2xPelVvYW1xbWNjWHpOMkd3QjNSUmt1MDM0UnlkVU50ZC1JUlVkMjh1VzVKTW54U0Q3d2x5QS1taklxTWZRUVdNX1B5dUMtNUtTSXlDdHppcUV4cnZTaHpkZWtxVGN0ZmlTNUZCRE1uellGZm10QjFQalhQQ3l5WHZEODFLQkZFOUcySkxfZEFrV19n?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NMRA Stock Price and Chart \u2014 NASDAQ:NMRA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE4zdnptN2gxMlBkY1p2MzU1aDFJQl9wUkt4WTQzSEx3VWlDNDIwZzUzYzFicTE3Umw0YWFUWHhGTi10czRKdm8tdzJTd3VMQ3lGanRuVjFuYVVrMVBu?oc=5", "source_name": "TradingView", "published_at": "2026-04-18T07:00:00+00:00", "published_display": "18 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics (NMRA) Is Among the Best Penny Stocks Set to Explode", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPWTR5NF9IWUJMazF1bUh3ZjNvYzNVSlVzNEpXcjBmQWZrNjR1alBnUHVkdS1ONEhSdS1lTGhNSkxGcmlvby1ESDV3OGRxSkpDcXBVNmdQWGRtZDdIb09DM0dfUjFnWlUwaUpSZ3RDd1IwNHJmazMwM3BycFZMcy1Nd1RqZlFBYl9xVERaS2FnSDFSUFc4NWQxOUROb1FsVldDd1Z1b2VJQnM?oc=5", "source_name": "Market source", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora lines up April 13 Needham healthcare conference webcast", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPT1hzS0lBSktyYXVUMUlNMHRoSnVJLVdQUGJtN0p3RU16RjJ4QWlmT2lMQlFKZWRKUGlfdDhBSTJERmtHZkEwN3V4MlVtYW1lVnRsRzVkZjZMVFA3R0dSU1E1ZmtfYW1zMTBjdGtCbWcxQ3c5c3NFcGJfX1FKcTBQSEg0NnpYamJuWHlBanBidXVPRktwSUo1V0xkZXJuRVBmZ2MxZEpvRTgyZ0Rvay0xUHVVZGlIRnJSbmJHaDVR?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics (NMRA) Positioned to Capitalize on Blockbuster Opportunity", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQMEhoZWJJeU1xMklfcWNOaVkxeVhtcDlKeXBKMGtyT1J0ZHQ0cnhySHJEQmZNaEJ6OG1obnE2TTFSbFRVS0NtcDJhUTcyc3N0Y1NFNlJlVGh2enlWNG1lMG01elRtY0k5Zy11cXNhNXIzaTlTZ2txUk9nWHJmNTEta0lEUC1EMGtHUFM3Sld2NEN6RnFGek1waw?oc=5", "source_name": "Market source", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics Inc (NMRA) Sheds More Light on Phase 1b Study of NMRA-511", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQT2tmOUJ3akZkZ1RabVVxZTdDQTVCb1hGTHBxYXAyXzJuS2lkS3NqREFFRElscTJGU0szRzhLVHQwYk9fb2JrTDFkNFhfOHhJNzN5ZWFfM1VVOWdlT1Rnd0xuWE9Tc0RsejhXckEtMHN6cVB5QWthY21zbUpBMlhNYlBzUXd3Mjdk?oc=5", "source_name": "Market source", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Neumora Therapeutics\u2019 (NMRA) Guggenheim Spotlight Recast Its Core Neuroscience Investment Narrative?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxPcUV1QVJfWGNVQWwxZ1NyY216OS1jaW5xeXRlOE1iOUdpcHhxYzE3N2tnNFpuN0x5RmU1SUJWQXFlaGdzVUd5RW5pT29nMGdzUWJ6a3M0b1N5SkhPTklpZmtGcm1sR0U1ZmJMbExEUlBpbHhFVUM0X1A5YmJnNld1dmpmS3ZwaEdRWWliZkdmcjctT1FLdmlkLVdTRXJuQ2hrMk41STZRS2J6SzdkdEJIVDEzS1owSkJQSDJEWk14ZkllRXJ3SllseXViNGQ4LWxaZjQzMnp5X1RWZHVOMl9VMTJMMjdXMk9MVHfSAe8BQVVfeXFMT3RTMmswd0VnSDFNZVlRSkdLcVR4b0RHcjhVdE1kM0NMQXFIZDY5bG1lNF9tZ1FRbE50VjE4Njd5YnhmclNTUFI4QVc0MUZhOXgzX25wTXZ1M0gtSXlMOVZ1RXdMby1BbFlVNlVUcFIyZ2tKMTE2eldibjVYcUN2T1dabXNDcjlJUWlqZlVjVVJONldpT1RQOGRNeExGV2tIZEVzdlYzYWFLNkw0X3E0M2FrLWhCM3ZNaHN4N2lTemhVVEtiQUhrT2RDMXBnRnllNmcxc2haOE9XSktIX0EtRWVhNVUzaHg5aDF6VEhSaGc?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Sees Upside Potential in Neumora Therapeutics (NMRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNTUxuVFFxQXMzalR2TXZTdldxTHh4R2JDc2pHTTNYUWZwZmd3MW9GR0dONlRpQnhZODVzakxubVNIR3VrTlluRXVwNjBLSTBRZUc0emJiNEJhWlV4OXhrdEN0UndTRG5BS1hLUFBlejZob3pTTFFjei1YUHd5RW5XZFhrWVZ5Zw?oc=5", "source_name": "Market source", "published_at": "2026-01-03T08:00:00+00:00", "published_display": "03 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics\u2019 Experimental Drug Demonstrates Weight Loss in Preclinical Studies", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxOSWhuQmR0WVFZU3plaC1BUXVkc0szYllCWTRJSFVadVFfVjVhRHN0MjJUM0R3QmJqUjdibDJ4ZWhNRFpMWVY2MUNtdm1zakZMNkk0bDJWRUI3amp6MDQySWpkT24yaV9ZT2lZaVFodlBrMVRQVG1LcWtpYmVSQVhYV3YxakhVU1F1WmwzMkNmb2x5RlNMdVZPTVp3VVRBM0lhVEVJbUI0ZWNxUDBoTDh2YXVpV0IyWW40cS0teUFwWEdFQk9QZmR2a05McXpGd2xXYmpIbmxWdlFoWTRUWl85Y2NPam4?oc=5", "source_name": "Stocktwits", "published_at": "2025-10-26T07:00:00+00:00", "published_display": "26 Oct 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neumora Therapeutics to Host Virtual R&D Day Highlighting Innovative Therapeutics Pipeline on October 27, 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNbjNYaTZ3MWdFSnJPand6VmVKX1lUUUYtQlVjVFpPX0FtODVKSEw0TmNUV1dqZzhqd003eFE2VFVpV3JuWkFGWU00WS1RSHNOV0tNbFlNdTZFcTZTSVBBS3c3ZFhXRTI5WnpqcDdYenBpNXpWamxzQmNfelNuVGNsQ21qTFk5dkc1N1BYWHBfNFdWUWRaeE5yWTZnd0hLZG4xb05yQkYwRXdfcGNXSTNsTGtnSllrOFdUeGZZQ2xSWjQ5bHZvWEpKMWZNdXpLWnN6d0l4VmJEOTlqRWNXX1ZvZQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-10-01T07:00:00+00:00", "published_display": "01 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NEUMORA THERAPEUTICS, INC. (NASDAQ: NMRA) DEADLINE ALERT:", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAJBVV95cUxOSHpiejJZZmdvX2dUTnRuWkt6SVYtZm1PSkhFbXVneTlSQmcxMDBEd2VnUndqd2g3NUFQR0NtRXFuVEZoOC1qRHFhNXpyUXh5YUltOHFoTzd4b0lOTkdSRkZIWS1JQWFZUXZfVE9MRUQtdm4wd05pckZZNFNocldjQkgtZXRJY3VUTEdIVDcyTTItQk94c3BNeXNzMzVWUUpscl9idXdCZ2k5SlBqVVRoUEZhUk5Ga2pYVEVrVXNTdGFjSnJwLVZsR2lfTWlsMDVYNk91LTV5eFZheEwyQlBnYnVtRVFuWFc5ZVQ4S043bFctR2hBbjk3OTYwNWd6VzYzemVyeXBxYmpCQndBZENYc1FOcXZHWV9CSUFZQlMzNllGSk1FY0l1RnJlY3I2M01JRjZXOQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-02-18T08:00:00+00:00", "published_display": "18 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQSW9mM3I5d1lnaHgzVDlPNFgzSVg3MFNNVmk0N0hLcGh3dko0MF9kWUVzS1phTmdDU1NjUGFZamZZWTBmdnFfanllME9NWmhxd0JiMjJzM3JCQU9SVnY0cEx3T3JnT1pDUlh3Vy0xR1lDem9hZ2ZqdUFXd2UzU1JRbkczUEdHZ1hSRGdTN1JfSHgtLUxQVTBJRjNGbS15Z05pZVd0a25wZl9OX0VjNnp4WHVVOUxxeUVwbTJ1TmdMTzZvcEZVbTkzSDdEUFhvZTdtZC1fb3R2SFZ4ZzQ?oc=5", "source_name": "StockStory", "published_at": "2026-07-15T07:00:00+00:00", "published_display": "15 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 59, "sentiment_summary": {"positive": 17, "negative": 15, "neutral": 27, "score": 51, "total": 59, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 18.5, "count": 33}, {"event": "analyst", "label": "Analyst action", "weight": 5.5, "count": 10}, {"event": "earnings", "label": "Earnings", "weight": 4.81, "count": 11}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.9, "count": 4}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 17, "negative_events": 15}, "market_context": {"has_market_context": true, "latest_close": 1.68, "latest_week": "2026-07-10", "one_week_move": 0.6, "four_week_move": -5.6, "twelve_week_move": -21.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.749385, "market_dynamics_buy_signal": false, "relative_strength": -31.610658, "fair_value_gap": -75.2, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 51.1916, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.6% over one week, -5.6% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 49, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 14}, {"label": "TradingView", "count": 7}, {"label": "www.marketscreener.com", "count": 5}, {"label": "marketscreener.com", "count": 4}, {"label": "Moomoo", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "MarketBeat", "count": 2}, {"label": "Timothy Sykes", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 50}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 33}, {"label": "Earnings", "count": 11}, {"label": "Analyst action", "count": 10}, {"label": "Regulatory and legal", "count": 4}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "50", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.6% over one week, -5.6% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Neumora Therapeutics Target of Unusually Large Options Trading (NASDAQ:NMRA)"}], "updated_at": "2026-07-16T18:57:37.428067+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}